Active Ingredient(s): Idursulfase
FDA Approved: * July 24, 2006
Category: Enzymes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Elaprase Overview

Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II).[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line. It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[2][3][4] References ^ .mw-parser-output cite.citation{font-style:inherit}.m...

Read more Elaprase Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Idursulfase

Recent Elaprase Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 6mg/3ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Elaprase: (1 result)

Sorted by National Drug Code
  • 54092-700 Elaprase 6 mg/3ml Intravenous Solution, Concentrate by Shire Us Manufacturing Inc.

Other drugs which contain Idursulfase or a similar ingredient: (1 result)